Rezolute, Inc.

(RTTNews) - Rezolute, Inc. (RZLT) on Wednesday announced the pricing of an underwritten offering of approximately $90 million in gross proceeds, consisting of common stock and pre-funded warrants, to support its continued development of therapies for rare diseases, including congenital hyperinsulinism or HI.
The offering includes 20,786,923 shares of common stock at $3.25 per share, and 6,905,385 pre-funded warrants at $3.2490 per warrant.
The company has also granted underwriters a 30-day option to purchase up to an additional 4,153,846 shares of common stock.
All securities are being sold by Rezolute, and the offering is expected to close on or around April 24, 2025, subject to customary closing conditions.
Rezolute stated that proceeds will be used to fund research and development, general corporate purposes, and working capital.
The offering received participation from new and existing institutional investors, including Federated Hermes Kaufmann Funds, Blackstone Multi-Asset Investing, Great Point Partners, Nantahala Capital, Marshall Wace, Squadron Capital Management, and Woodline Partners.
Rezolute is advancing ersodetug, a monoclonal antibody therapy for hyperinsulinism, through late-stage development. The company is currently enrolling patients in the Phase 3 sunRIZE study, with topline data expected by the end of 2025.
Currently, RZLT is trading at $3.97 up by 27.49 percent on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Rezolute Raises $90 Mln Through Stock And Warrant Offering To Support HI Drug Pipeline

In trading on Monday, biotechnology shares were relative leaders, up on the day by about 2%. Leading the group were shares of Agenus, up about 20.7% and shares of Rezolute up about 17.1% on the day.
Also showing relative strength are drugs shares, up on the day by about 1% as a group, led by Terns Pharmaceuticals, trading higher by about 15.2% and Sagimet Biosciences, trading higher by about 14.2% on Monday.
VIDEO: Monday Sector Leaders: Biotechnology, Drugs
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Monday Sector Leaders: Biotechnology, Drugs

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.
At Rezolute (RZLT), a filing with the SEC revealed that on Sunday, Young-jin Kim purchased 1,250,000 shares of RZLT, for a cost of $4.00 each, for a total investment of $5M. Kim was up about 18.8% on the buy at the high point of today's trading session, with RZLT trading as high as $4.75 at last check today. Rezolute is trading down about 0.4% on the day Thursday. Before this latest buy, Kim made one other buy in the past twelve months, purchasing $369,858 shares at a cost of $3.20 each.
And on Tuesday, Director Michael F. Mahoney purchased $2.00M worth of CVS Health (CVS), purchasing 30,000 shares at a cost of $66.70 each. Before this latest buy, Mahoney made one other buy in the past twelve months, purchasing $500,294 shares for a cost of $54.49 each. CVS Health is trading off about 0.5% on the day Thursday. Investors are able to snag CVS at a price even lower than Mahoney did, with shares changing hands as low as $65.71 at last check today which is 1.5% under Mahoney's purchase price.
VIDEO: Thursday 2/20 Insider Buying Report: RZLT, CVS
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Thursday 2/20 Insider Buying Report: RZLT, CVS

(RTTNews) - Rezolute, Inc. (RZLT),a late-stage biopharmaceutical company, Tuesday said that the U.S. Food and Drug Administration or FDA has granted orphan drug designation to ersodetug for the treatment of hypoglycemia due to tumor hyperinsulinism (HI).
Orphan Drug Designation offers benefits including seven years of market exclusivity after approval, tax credits for clinical trials, and potential qualification for expedited pathways to approval.
A Phase 3 Registrational trial of ersodetug in patients with hypoglycemia due to tumor HI is expected to start in 2025.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Rezolute's Ersodetug Gets Orphan Drug Designation To Treat Hypoglycemia Due To Tumor Hyperinsulinism

Health care stocks fell Monday with the NYSE Health Care Index down 2.9% and the Health Care Select Sector SPDR Fund (XLV) dropping 2.6%.
The iShares Biotechnology ETF (IBB) fell 2.8%.
In corporate news, BioNTech (BNTX) reported a wider-than-expected loss in Q2 as global sales of the German drugmaker's COVID-19 vaccine fell amid weak demand. The stock slumped 4.4%.
Moderna (MRNA) is facing "material headwinds" for its vaccines for respiratory syncytial virus and COVID, RBC Capital Markets said in a report. RBC downgraded Moderna to sector perform from outperform and cut its price target to $90 from $125. Moderna shares were falling 3.3%.
Rezolute (RZLT) shares rose 2.3% after the company obtained US Food and Drug Administration clearance for an investigational new drug application for a phase 3 trial of RZ358 to treat hypoglycemia in people with tumor hyperinsulinism.
Actinium Pharmaceuticals (ATNM) shares plunged 60% after the US Food and Drug Administration determined that a phase 3 trial of Iomab-B to treat relapsed or refractory acute myeloid leukemia isn't adequate to support a biologics license application.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Sector Update: Health Care Stocks Fall Monday

Health care stocks were lower Monday afternoon, with the NYSE Health Care Index falling 2.2% and the Health Care Select Sector SPDR Fund (XLV) dropping 2.5%.
The iShares Biotechnology ETF (IBB) fell 2.8%.
In corporate news, Moderna (MRNA) is facing "material headwinds" for its vaccines for respiratory syncytial virus and COVID, RBC Capital Markets said in a report. RBC downgraded Moderna to sector perform from outperform and cut its price target to $90 from $125. Moderna shares were falling almost 3%.
Rezolute (RZLT) shares rose 1% after the company said it has obtained US Food and Drug Administration clearance for an investigational new drug application for a phase 3 trial of RZ358 to treat hypoglycemia in people with tumor hyperinsulinism.
Actinium Pharmaceuticals (ATNM) shares plunged 66% after the US Food and Drug Administration determined that a phase 3 trial of Iomab-B to treat relapsed or refractory acute myeloid leukemia isn't adequate to support a biologics license application. The firm said the FDA needs additional head-to-head trial demonstrating overall survival benefit with Iomab-B to support a BLA filing.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Sector Update: Health Care Stocks Fall in Afternoon Trading

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.
On Friday, Lemonade's Chief Financial Officer, Timothy E. Bixby, made a $304,650 buy of LMND, purchasing 20,000 shares at a cost of $15.23 a piece. Lemonade is trading up about 4.3% on the day Tuesday. Before this latest buy, Bixby made one other purchase in the past twelve months, buying $165,400 shares for a cost of $16.54 a piece.
And at Rezolute, there was insider buying on Friday, by CFO Daron Evans who purchased 40,000 shares for a cost of $4.04 each, for a total investment of $161,568. Before this latest buy, Evans bought RZLT at 3 other times during the past year, for a total investment of $139,843 at an average of $1.92 per share. Rezolute is trading up about 1% on the day Tuesday. Bargain hunters are able to snag RZLT even cheaper than Evans did, with shares changing hands as low as $3.84 in trading on Tuesday which is 4.9% below Evans's purchase price.
VIDEO: Tuesday 6/18 Insider Buying Report: LMND, RZLT
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tuesday 6/18 Insider Buying Report: LMND, RZLT

(RTTNews) - Every investor aspires to see the stocks in their portfolio deliver substantial returns. Though trading is a game of probabilities, with both wins and losses, some investors manage to hit the jackpot.
The following compilation represents a selection of stocks featured on our website that reached new 52-week high levels during the current week. However, please note that this list is not comprehensive and does not encompass all the stocks that achieved this milestone.
Protagonist Therapeutics Inc. (PTGX)
Protagonist is a clinical-stage biopharmaceutical company with multiple assets having billion-dollar market potential.
The company has a worldwide license and collaboration agreement with Takeda for investigational drug Rusfertide under development for polycythemia vera and other blood disorders. A phase III trial evaluating Rusfertide in polycythemia vera, dubbed VERIFY, is underway, and top-line data for the study's 32-week primary efficacy endpoint is anticipated by the end of the first quarter of 2025.
Next up is JNJ-2113 (formerly known as PN-235), being developed pursuant to the license and collaboration agreement between Protagonist and Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. JNJ-2113 is under phase III trials in moderate-to-severe plaque psoriasis and in a phase IIb trial in moderately to severely active ulcerative colitis.
PTGX was featured on our site on Mar.7, 2023, when it was trading around $16.97. The stock closed yesterday's trading at $34.02, reflecting an impressive 100% gain from our published price.
Calliditas Therapeutics AB (publ) (CALT)
Calliditas is a Sweden-based commercial-stage biopharma company developing novel treatments for orphan indications with significant unmet medical needs.
The company's lead drug is Nefecon, marketed under the brand name Tarpeyo, to reduce proteinuria in adults with primary immunoglobulin A nephropathy. The drug, which was granted accelerated approval by the FDA in Dec.2021, received full approval in Dec.2023.
Tarpeyo is also marketed in EEA, Switzerland and the UK under the brand name Kinpeygo. In the EU, Kinpeygo was granted conditional marketing authorisation in July 2022, and awaits the full approval in August of this year.
For the first quarter ended March 31, 2024, net sales of Tarpeyo were $26.8 million compared to $17.8 million in the year-ago quarter. Preliminary net sales of Tarpeyo for the second quarter of 2024, are estimated to be $25.5 million compared to $25 million in the second quarter of 2023.
CALT was featured on our site on Mar.13, 2023, when it was trading around $22.60. The stock closed yesterday's trading at $41.41, and that implies a gain of 83% from our published price.
Stoke Therapeutics Inc. (STOK)
Stoke is a clinical-stage biotechnology company developing RNA-based medicines. Its lead drug candidate is STK-001, which is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.
The company is planning to meet with regulatory agencies to discuss its plans for a randomized, controlled registrational study for STK-001 and an update related to this is expected in the second half of 2024.
Our site featured STOK on Apr.14, 2023, when its trading price was hovering around $8.77. Remarkably, the stock closed at $15.21 yesterday, reflecting a 73% upswing in value from our published price.
Halozyme Therapeutics Inc. (HALO)
Halozyme is a biopharmaceutical company, whose ENHANZE drug delivery technology is licensed to pharma and biotech companies, including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.
The company commercializes specialty products like adjuvant Hylenex; testosterone replacement therapies like XYOSTED and TLANDO; and NOCDURNA, which is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Revenue is also generated from ENHANZE collaborations and from the sales and/or royalties of its approved products.
For full year 2024, the company anticipates total revenue of $935 million to $1,015 million, representing growth of 13% to 22% over 2023, primarily driven by increases in royalty revenue, collaboration revenue and growth in product sales from XYOSTED.
Our site featured HALO on July 13, 2023, when its trading price was around $37.55. The stock closed at $51.44 yesterday, reflecting a decent gain of 37% from our published price.
PepGen Inc. (PEPG)
PepGen is a clinical-stage biotechnology company developing therapeutics for the treatment of severe neuromuscular and neurological disorders. The lead drug candidate is PGN-EDO51, under phase II testing for the treatment of Duchenne Muscular Dystrophy. Also in the pipeline is PGN-EDODM1, under phase I trial for Myotonic Dystrophy 1.
The company anticipates reporting preliminary data from the phase I trial of PGN-EDODM1, dubbed FREEDOM-DM1 in the second half of 2024.
We highlighted PEPG on our site on Oct.12, 2023, when it was trading around $5.23. The stock closed yesterday's trading at $17.34, marking an impressive gain of 231% from our published price.
Agios Pharmaceuticals Inc. (AGIO)
Agios Pharma, pioneering therapies for rare diseases, is a commercial-stage company. Its flagship drug is Mitapivat, approved for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency in the U.S., EU and Great Britain, under the brand name Pyrukynd.
Early this month, Agios announced that its phase III study of Mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia, dubbed ENERGIZE-T, met the primary endpoint of transfusion reduction response.
AGIO was trading around $21.20 when it was highlighted on our site on Nov.3, 2023. The stock closed yesterday's trading at $47.80, implying a gain of 125% from our published price.
Vertex Pharmaceuticals Inc. (VRTX)
Vertex Pharma is a global biotechnology company that has approved medicines for cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia.
For full year 2024, the company expects total product revenue to be in the range of $10.55 billion to $10.75 billion. The product revenue was $9.87 billion in 2023.
VRTX was featured on our site on Jan.3, 2024, when it was trading around $412.43, The stock closed yesterday's trading at $485.53, implying a decent gain of 17% from our published price.
ADMA Biologics Inc. (ADMA)
ADMA Biologics is a commercial biopharmaceutical company developing specialty plasma-derived products for the prevention and treatment of infectious diseases in immune compromised and other patients at risk for infection.
When reporting first quarter financial results last month, the company made significant increases to both top- and bottom-line projections for 2024 and 2025.
The total revenue for full year 2024 is now expected to be more than $355 million, up from its prior guidance of over $330 million. The total revenue was $258 million in 2023.
Looking ahead to 2025, the total revenue is now projected to be more than $410 million, up from its earlier estimate of over $380 million.
We featured ADMA on our site on Feb.15, 2024, when it was trading around $5.36. The stock closed yesterday's trading at $10.58, reflecting an impressive 97% upswing from our published price.
Insmed Inc. (INSM)
Insmed is a revenue-generating global biopharmaceutical company. Its lead drug Arikayce is indicated for the treatment of Mycobacterium avium complex (MAC) lung disease in adults who have limited or no alternative treatment options.
For full year 2024, the company expects global Arikayce revenue to be in the range of $340 million to $360 million. The drug generated revenue of $305.2 million in 2023.
We highlighted INSM on our site on Mar.25, 2024, when it was trading around $26.52. The stock closed yesterday's trading at $57.17, marking a substantial 115% increase from our published price.
Rezolute Inc. (RZLT)
Rezolute is developing a drug for diabetic macular edema by the name RZ402.
Last month, the company reported positive topline results from its phase II clinical study of RZ402 in patients with DME who are naïve to or have received limited anti-vascular growth factor (anti-VEGF) injections.
We featured RZLT on our site on Apr.1, 2024, when it was trading around $2.68. The stock closed yesterday's trading at $5.59, exhibiting a notable 108% rally from our published price.
Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus is a global messenger RNA medicine company. Its lead product Kostaive, a self-amplifying mRNA COVID-19 vaccine for primary vaccination and booster for adults 18 years and older, developed in partnership with CSL, is expected to be launched in Japan this year. The vaccine was approved by Japan's Ministry of Health, Labor and Welfare last November.
The company also has two wholly owned mRNA therapeutic candidates in clinical development - ARCT-032 for Cystic Fibrosis and ARCT-810 for ornithine transcarbamylase (OTC) deficiency.
New Phase 1b interim data for ARCT-032 will be presented at European Cystic Fibrosis Conference today.
ARCT was featured on our site on Apr.9, 2024, when it was trading around $30.83. The stock closed yesterday's trading at $42.60, representing a gain of 38% from our published price.
Novavax Inc. (NVAX)
Novavax is a global company advancing protein-based vaccines with its Matrix-M adjuvant. This Covid-vaccine maker signed a licensing deal worth $1.2 billion with Sanofi last month.
For the first quarter ended Mar.31, 2024, total revenue was $94 million, compared to $81 million in the same period in 2023.
Novavax is aiming to deliver JN.1 protein-based non-mRNA COVID-19 vaccine this Fall.
We profiled NVAX on our site on May 13, 2024, when it was trading around $9.69. Yesterday's closing price of $19.56 implies a 101% appreciation from our published price.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

These Biotech Stocks Hit New Highs, Did You Reap The Rewards?

June S&P 500 E-Mini futures (ESM24) are trending down -0.11% this morning as market participants awaited minutes of the Federal Reserve’s latest policy meeting as well as an earnings report from artificial intelligence bellwether Nvidia.
In yesterday’s trading session, Wall Street’s main stock indexes ended in the green. First Solar (FSLR) climbed over +8% and was the top percentage gainer on the S&P 500 after UBS and Piper Sandler raised their price targets on the stock. Also, Tesla (TSLA) advanced more than +6% and was the top percentage gainer on the Nasdaq 100 as a coalition of Tesla shareholders is urging peers to oppose a $56 billion pay package for CEO Elon Musk and to vote against the reelection of directors Kimbal Musk and James Murdoch, citing concerns that the board is not acting in the company’s best interests. In addition, International Business Machines (IBM) rose over +2% and was the top percentage gainer on the Dow after the tech giant revealed several artificial intelligence updates. On the bearish side, Nordson (NDSN) slumped more than -9% and was the top percentage loser on the S&P 500 after the company reported weaker-than-expected Q2 sales and cut its full-year guidance. Also, Palo Alto Networks (PANW) fell over -3% after the cybersecurity company gave a Q4 billings forecast that disappointed investors.
Fed Governor Christopher Waller said Tuesday that he needs to see several more favorable inflation reports before considering interest-rate cuts, adding that keeping rates steady for “three or four” months won’t harm the economy. “In the absence of a significant weakening in the labor market, I need to see several more months of good inflation data before I would be comfortable supporting an easing in the stance of monetary policy,” Waller said. In a discussion following his prepared remarks, he added that he expects the next move in borrowing costs will be downward. Also, Atlanta Fed President Raphael Bostic stated that the central bank will be in a position to begin cutting interest rates “by the end of the year,” though he does not anticipate this happening before the fourth quarter. In addition, Fed Vice Chair for Supervision Michael Barr reiterated that officials should keep interest rates steady for a longer duration than previously anticipated to effectively cool inflation. Finally, Cleveland Fed President Loretta Mester stated her preference for observing “a few more months of inflation data that looks like it’s coming down” before cutting interest rates.
Meanwhile, U.S. rate futures have priced in a 0% chance of a 25 basis point rate cut at the next central bank meeting in June and an 18.3% probability of a 25 basis point rate cut at the July FOMC meeting.
On the earnings front, major companies like Nvidia (NVDA), TJX Companies (TJX), Analog Devices (ADI), Target (TGT), and Snowflake (SNOW) are slated to release their quarterly results today.
Today, investors will also closely monitor the publication of the Federal Reserve’s minutes from the April 30-May 1 meeting to gauge how close the central bank is to lowering borrowing costs.
On the economic data front, investors will focus on U.S. Existing Home Sales data due later in the day. Economists, on average, forecast that April Existing Home Sales will stand at 4.21M, compared to the previous value of 4.19M.
U.S. Crude Oil Inventories data will be reported today as well. Economists estimate this figure to be -2.400M, compared to last week’s figure of -2.508M.
In the bond market, the yield on the benchmark 10-year U.S. Treasury note is at 4.437%, up +0.53%.
The Euro Stoxx 50 futures are down -0.38% this morning as investors digested Britain’s inflation data while awaiting the release of the Fed’s meeting minutes and Nvidia’s earnings. Automobile stocks led the declines on Wednesday following a report regarding potential Chinese tariffs on imported cars. The Office for National Statistics reported Wednesday that Britain’s annual inflation rate slowed less than expected in April, which could potentially delay interest rate cuts from the Bank of England. Meanwhile, investors are anticipating the release of minutes from the Fed’s latest policy meeting and Nvidia’s quarterly earnings to assess whether the recent market rally could continue. In corporate news, Marks And Spencer Group Plc (MKS.LN) gained over +8% after the British retailer posted a 58% increase in full-year profit and issued a strong outlook.
U.K.’s CPI and U.K.’s Core CPI data were released today.
U.K. April CPI has been reported at +0.3% m/m and +2.3% y/y, stronger than expectations of +0.2% m/m and +2.1% y/y.
U.K. April Core CPI arrived at +0.9% m/m and +3.9% y/y, stronger than expectations of +0.7% m/m and +3.6% y/y.
Asian stock markets today settled mixed. China’s Shanghai Composite Index (SHCOMP) closed up +0.02%, and Japan’s Nikkei 225 Stock Index (NIK) closed down -0.85%.
China’s Shanghai Composite Index closed just above the flatline today. Solar stocks rallied on Wednesday following an announcement by the China Photovoltaic Industry Association that it would enhance monitoring of industry competition. At the same time, home-appliance stocks retreated. Meanwhile, the first batch of China’s 1 trillion yuan ($138.14 billion) ultra-long special treasury bonds, which debuted on Wednesday, saw a more than 20% surge during the early session on the Shanghai and Shenzhen stock exchanges, prompting trading suspensions. In other news, a Chinese business group on Tuesday cautioned about potential tariff hikes on car imports in response to actions by the U.S. and the European Union regarding Chinese electric vehicles. In corporate news, Xpeng Inc. surged over +13% in Hong Kong after the Chinese electric vehicle maker reported stronger-than-expected Q1 results and projected higher revenue and deliveries in the second quarter.
Meanwhile, the Reserve Bank of New Zealand held rates steady for the seventh consecutive meeting on Wednesday and indicated that interest rate cuts might begin later in 2025.
Japan’s Nikkei 225 Stock Index closed lower today as investors digested disappointing trade data from the country, while concerns regarding higher borrowing costs also dampened sentiment. Real estate and pharmaceutical stocks underperformed on Wednesday. Data from the Ministry of Finance on Wednesday revealed that Japan’s trade deficit widened to 462.5 billion yen in April from 429.8 billion yen a year earlier as an 8.3% year-over-year export growth was offset by the higher value of imports due to a weaker yen. Separately, the Cabinet Office reported on Wednesday that Japan’s core machinery orders unexpectedly rose in March compared to the previous month. Meanwhile, Japan’s 10-year government bond yield hit the psychological threshold of 1.0% for the first time in 11 years on Wednesday, driven by rising expectations that the Bank of Japan may implement further tightening measures in the coming months. In corporate news, ERI Holdings climbed over +5% after the company announced it would buy Hokkaido-based Fukuda Hydrologic Center for 2.29 billion yen. The Nikkei Volatility, which takes into account the implied volatility of Nikkei 225 options, closed flat at 17.11.
The Japanese April Trade Balance has been reported at -462.5B yen, weaker than expectations of -339.5B yen.
The Japanese April Exports stood at +8.3% y/y, weaker than expectations of +11.1% y/y.
The Japanese April Imports came in at +8.3% y/y, weaker than expectations of +9.0% y/y.
The Japanese March Core Machinery Orders arrived at +2.9% m/m, stronger than expectations of -1.8% m/m.
Pre-Market U.S. Stock Movers
Rezolute (RZLT) soared about +50% in pre-market trading after announcing that a Phase 2 proof-of-concept study for its orally administered drug RZ402 achieved its primary endpoints in treating diabetic macular edema.
Urban Outfitters (URBN) climbed over +8% in pre-market trading after the retailer reported record profit and sales for the first quarter, topping Wall Street’s expectations.
Shopify (SHOP) advanced more than +3% in pre-market trading after Goldman Sachs upgraded the stock to Buy from Neutral with a price target of $74.
Edwards Lifesciences (EW) rose over +1% in pre-market trading after Citi upgraded the stock to Buy from Neutral with a price target of $105.
Kraft Heinz (KHC) gained about +1% in pre-market trading after Piper Sandler upgraded the stock to Overweight from Neutral with an unchanged price target of $42.
ViaSat (VSAT) plunged more than -11% in pre-market trading after the company said it expects “roughly flat” year-over-year revenue growth in fiscal 2025.
You can see more pre-market stock movers here
Today’s U.S. Earnings Spotlight: Wednesday - May 22nd
NVIDIA (NVDA), TJX (TJX), Analog Devices (ADI), Synopsys (SNPS), Target (TGT), Snowflake (SNOW), Williams-Sonoma (WSM), Vipshop (VIPS), VF (VFC), Dycom Industries (DY), Enersys (ENS), Golden Ocean (GOGL), BBVA Argentina (BBAR), Corporacion America Airports (CAAP), Brady (BRC), Liveramp (RAMP), ePlus (PLUS), GDS Holdings (GDS), Photronics (PLAB), Zuora (ZUO), Universal (UVV), Hovnanian Enterprises (HOV), REX American Resources (REX), Kingsoft Cloud (KC), WalkMe (WKME).
On the date of publication, Oleksandr Pylypenko did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	0.00 23.75
P/B	2.56 2.20
P/FCF	0.00 18.30

Indicator	TTM Median
ROE	-71.13 25.41
ROA	-63.30 6.00
Net Worth	0.30 0.20
Quick Ratio	0.00 1.71
Current Ratio	13.39 2.83

Indicator	TTM Median
EPS	0.22 0.37
EPS Forecast	0.35 0.37
Revenue	0.00 16.00M
Gross Profit	0.00 —
EBITDA	-24.00M —

Rezolute, Inc.

Indicators RZLT

Valuation

Debts

Efficiency

Other ratios

Revenue